Atorvastatin-20 · DIN 02411369 · 20 mg · tablet
General benefitMarketed · checked November 19, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible
• Then up to $6.11 per prescription
Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Atorvastatin-20 · DIN 02411369
Manufacturer: Sivem Pharmaceuticals ULC; listing date 2020-06-30
Health Canada: Marketed since 2013-10-23 · brand ATORVASTATIN-20 · ATC C10AA05 ATORVASTATIN · form Tablet · route Oral · ingredients ATORVASTATIN (ATORVASTATIN CALCIUM PROPYLENE GLYCOL SOLVATE) 20 MG · company Sivem pharmaceuticals ulc · schedule Prescription
Atorvastatin-20: Formulary list price $0.22 per unit (the source does not state the unit; exact figure $0.2179). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02411369)
Source record
DIN 02411369: Atorvastatin-20
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240600034; group id 296; item number 0647; lccId None; manufacturer id SIV
Source form: Tab; strength: 20mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.2179; ministry $0.2179
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02411369
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=89597
Interchangeable products
AG-Atorvastatin · DIN 02478153 · $0.2179
Ach-Atorvastatin Calcium · DIN 02457768 · $0.2179
Apo-Atorvastatin · DIN 02295288 · $0.2179
Atorvastatin · DIN 02348713 · $0.2179
Atorvastatin · DIN 02475030 · $0.2179
Atorvastatin · DIN 02545470 · $0.2179
Auro-Atorvastatin · DIN 02407264 · $0.2179
Bio-Atorvastatin · DIN 02481197 · $0.2179
Jamp Atorvastatin Calcium · DIN 02504200 · $0.2179
Jamp-Atorvastatin · DIN 02391066 · $0.2179
Lipitor · DIN 02230713 · $0.2179
M-Atorvastatin · DIN 02471175 · $0.2179
Mar-Atorvastatin · DIN 02454025 · $0.2179
Mint-Atorvastatin · DIN 02479516 · $0.2179
Mylan-Atorvastatin · DIN 02392941 · $0.2179
NRA-Atorvastatin · DIN 02476525 · $0.2179
PMS-Atorvastatin · DIN 02477157 · $0.2179
PMSC-Atorvastatin · DIN 02507242 · $0.2179
PRZ-Atorvastatin · DIN 02521563 · $0.2179
Ratio-Atorvastatin · DIN 02350319 · $0.2179
Reddy-Atorvastatin · DIN 02417944 · $0.2179
Sandoz Atorvastatin · DIN 02324954 · $0.2179
Taro-Atorvastatin · DIN 02313715 · $0.2179
Teva-Atorvastatin · DIN 02310902 · $0.2179
Shortage status: not checked (no credentials)